Article
Hematology
Danielle Carole Roy, Tzu-Fei Wang, Marc Carrier, Ranjeeta Mallick, Dylan Burger, Steven Hawken, Philip S. Wells
Summary: Inherited thrombophilia and cancer can both increase the risk of VTE and bleeding in chemotherapy patients. Our study found that FVL mutation and ABO blood type may be important predictors of VTE in cancer patients starting chemotherapy.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
David Spirk, Tim Sebastian, Stefano Barco, Martin Banyai, Juerg H. Beer, Lucia Mazzolai, Thomas Baldi, Drahomir Aujesky, Daniel Hayoz, Rolf P. Engelberger, Thomas Kaeslin, Wolfgang Korte, Robert Escher, Marc Husmann, Marc Blondon, Nils Kucher
Summary: In patients with cancer-associated venous thromboembolism (VTE), the risk of recurrence is similar after incidental and symptomatic events. It is unknown whether the same applies to incidental VTE not associated with cancer. After comparing baseline characteristics, anticoagulation therapy, all-cause mortality, and VTE recurrence rates at 90 days between patients with incidental and symptomatic VTE, the study found that receiving anticoagulation therapy for at least 3 months was associated with lower mortality and recurrence rates in patients with incidental VTE regardless of cancer status. Additionally, among noncancer patients, early mortality and recurrence rates were similar after incidental versus symptomatic VTE.
THROMBOSIS AND HAEMOSTASIS
(2021)
Review
Oncology
Lai Heng Lee, Pongwut Danchaivijitr, Noppacharn Uaprasert, Harinder Gill, Dennis Lee Sacdalan, Gwo Fuang Ho, Rajiv Parakh, Paresh Pai, Jen-Kuang Lee, Nannette Rey, Alexander T. Cohen
Summary: Direct oral anticoagulants (DOACs) have shown comparable efficacy and safety outcomes in Asian patients with cancer-associated thrombosis (CAT) compared to other races. Apixaban, edoxaban, or rivaroxaban can be considered as reasonable alternatives to low-molecular-weight heparin (LMWH) for anticoagulation in Asian patients with CAT.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Mario Enrico Canonico, Ciro Santoro, Marisa Avvedimento, Giuseppe Giugliano, Giulia Elena Mandoli, Maria Prastaro, Anna Franzone, Raffaele Piccolo, Federica Ilardi, Matteo Cameli, Giovanni Esposito
Summary: Acute thrombotic events can reveal occult cancer in a significant number of cases. Malignancy interacts with the hemostatic system, leading to both thrombosis and bleeding. Cancer-related thrombotic events primarily affect the venous side and present in various conditions, including unusual sites of venous thrombosis. The selection of patients for anticoagulation management is complex, taking into account individual patient goals and preferences, prognosis of specific cancers, comorbidities, drug interactions, underweight states, and competing risks of morbidity and mortality. Anticoagulant treatment in cancer is widely debated, with direct oral anticoagulants showing efficacy and safety compared to traditional treatment.
Review
Medicine, General & Internal
Ann-Rong Yan, Indira Samarawickrema, Mark Naunton, Gregory M. Peterson, Desmond Yip, Reza Mortazavi
Summary: This study aims to investigate the available VTE risk assessment tools for ambulatory patients with lung cancer and compare their predictive performance. Systematic evaluation and meta-analysis will be conducted to determine the incidence of VTE and the performance of the risk models included in the studies.
Article
Oncology
Jingyi Gong, Zsofia D. Drobni, Raza M. Alvi, Sean P. Murphy, Ryan J. Sullivan, Sarah E. Hartmann, Hannah K. Gilman, Hang Lee, Leyre Zubiri, Vineet K. Raghu, Rebecca S. Karp-Leaf, Amna Zafar, Daniel A. Zlotoff, Matthew J. Frigault, Kerry L. Reynolds, Tomas G. Neilan
Summary: The study found that the risk of VTE was 7.4% at 6 months and 13.8% at 1 year after starting an ICI, with a significantly increased rate of VTE. Factors such as age, medical history, and underlying diseases can predict the risk of VTE in patients receiving ICIs.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Ming-Yee Sun, Sonu M. M. Bhaskar
Summary: This article provides an updated overview of the therapeutic and preventive strategies for strokes in cancer settings, emphasizing the distinct challenges and the need for individualized diagnostic and treatment approaches. The strategies discussed include acute reperfusion therapy, anticoagulant therapy, antiplatelet therapy, and lifestyle management options. The article highlights the limited guidelines and evidence-based clinical management for cancer-related strokes and thromboembolisms, and offers future recommendations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Hematology
Damon E. Houghton, Waldemar E. Wysokinski, Leslie J. Padrnos, Surbhi Shah, Ewa Wysokinska, Rajiv Pruthi, Atefeh Ghorbanzadeh, Aneel Ashrani, Meera Sridharan, Robert D. McBane, Anand Padmanabhan, Ana I. Casanegra
Summary: This study aimed to investigate the risk of venous thromboembolism (VTE) in patients with thrombophilia who received COVID-19 vaccinations. The analysis of electronic medical records from November 1, 2020, to November 1, 2021, showed no increased risk of acute VTE after vaccination compared to the pre-vaccination period in this subgroup of patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Review
Hematology
Florian Moik, Alexander Makatsariya, Cihan Ay
Summary: Patients with cancer undergoing chemotherapy are at risk of thrombocytopenia, which increases the risk of VTE. Managing cancer-associated VTE in the setting of chemotherapy-induced thrombocytopenia is challenging without high-quality studies.
THROMBOSIS RESEARCH
(2021)
Review
Oncology
Hatice Bolek, Yuksel Urun
Summary: Cancer-associated thrombosis is a significant problem in cancer patients, and risk stratification scores or biomarkers are needed to identify patients who can benefit from prophylaxis with low bleeding risk. Low molecular weight heparins and direct oral anticoagulants are effective and safe treatment options for cancer-associated thrombosis.
Review
Cell Biology
Viktoria Muster, Thomas Gary
Summary: Glioblastoma patients have a high risk of developing venous thromboembolism, making therapeutic anticoagulation challenging with limited data available for this vulnerable patient group.
Review
Hematology
Wei Xiong
Summary: Patients with cancer are at a higher risk of developing VTE, which poses challenges in treatment due to the complexity of managing VTE in cancer patients. Therapeutic anticoagulation is crucial in the treatment of cancer-associated VTE, with options like LMWH and DOACs showing promise but requiring careful consideration. Guidelines from ASCO, ITAC, and NCCN provide recommendations for the treatment of cancer-associated VTE based on various clinical trials and meta-analyses.
THROMBOSIS JOURNAL
(2021)
Article
Hematology
C. Heleen van Ommen, Klasien A. Bergman, Marit Boerma, Heleen A. Bouma, Albertine E. Donker, Melissa Gouvernante, Christian Hulzebos, Dalila Khandour, Ronny Knol, Marlou A. Raets, K. Djien Liem, Richard A. van Lingen, Moniek van de Loo, Enrico Lopriore, Mayke van der Putten, Jeanine J. Sol, Monique H. Suijker, Daniel C. Vijlbrief, Remco Visser, Mirjam M. van Weissenbruch
Summary: A national management guideline was developed in the Netherlands to create uniform management for catheter-related venous thromboembolism (CVTE) in critically ill (preterm) neonates. A prospective observational study of 115 infants showed that following the guideline led to a low incidence of recurrent venous thrombotic events and death due to CVTE, but major bleeding occurred in a small percentage of infants.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Public, Environmental & Occupational Health
Mauro Turrini, Catherine Bourgain
Summary: The use of individual genomic risk factors for predicting common diseases is an important aspect of personalized medicine. This paper examines the impact of genetic susceptibility on clinical practice through a case study of non-rare thrombophilia tests. The tests were quickly adopted by clinicians but faced controversy over their clinical utility when epidemiological evaluations showed limited predictive capacity.
SOCIAL SCIENCE & MEDICINE
(2022)
Review
Medicine, General & Internal
Xiaole Su, Bingjuan Yan, Lihua Wang, Hong Cheng, Yipu Chen
Summary: DOACs have similar efficacy as warfarin in the treatment of acute VTE, reducing recurrent VTE and VTE-related death, but are significantly superior to warfarin in reducing the risk of bleeding. There is no significant difference in the efficacy and safety of DOACs across different CrCl stratifications, but apixaban might be associated with a lower risk of bleeding in patients with VTE and CrCl >80 mL/min.